These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35760920)

  • 1. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
    Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
    Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.
    Huang DP; Yang LC; Chen YQ; Wan WQ; Zhou DH; Mai HR; Li WL; Yang LH; Lan HK; Chen HQ; Guo BY; Zhen ZJ; Liu RY; Chen GH; Feng XQ; Liang C; Wang LN; Li Y; Luo JS; Fan Z; Luo XQ; Li B; Tang YL; Zhang XL; Huang LB
    Blood Cancer J; 2023 Dec; 13(1):178. PubMed ID: 38052803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: A case series.
    Fang YG; Huang SL; Chen NN
    J Integr Med; 2024 Sep; 22(5):614-620. PubMed ID: 39183097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
    Luo JS; Zhang XL; Huang DP; Chen YQ; Wan WQ; Mai HR; Chen HQ; Wen H; Liu RY; Chen GH; Li Y; Luo XQ; Tang YL; Huang LB
    Ann Hematol; 2023 Jul; 102(7):1713-1721. PubMed ID: 37199788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
    J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
    Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
    Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
    Zhu HH; Guo ZP; Jia JS; Jiang Q; Jiang H; Huang XJ
    Leuk Res; 2018 Feb; 65():14-19. PubMed ID: 29232592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
    Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
    Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
    Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
    Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
    J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
    Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
    J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
    Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial.
    Luo S; Tian J; Sun X; Wu F; Liu Y; Wan W; She Z; Wen C
    Evid Based Complement Alternat Med; 2022; 2022():8314176. PubMed ID: 35836830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
    Wang J; Huang JB; Liu ZL; Zhang BH; Xu HG; Xue HM; Chen C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1605-1610. PubMed ID: 29262883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
    Zhu HH; Hu J; Lo-Coco F; Jin J
    Blood; 2019 Aug; 134(7):597-605. PubMed ID: 31113776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
    Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
    Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
    Jiang H; Liang GW; Huang XJ; Jiang Q; Han S; Shi LW; Zhu HH
    Leuk Res; 2015 Dec; 39(12):1319-24. PubMed ID: 26403986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
    Ma YF; Lu Y; Wu Q; Lou YJ; Yang M; Xu JY; Sun CH; Mao LP; Xu GX; Li L; Huang J; Wang HY; Lou LJ; Meng HT; Qian JJ; Yu WJ; Wei JY; Li ZY; Zhu XL; Yan XY; Chen SN; Jin J; Zhu HH
    J Hematol Oncol; 2022 Oct; 15(1):148. PubMed ID: 36258250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.